Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hatzl, S; Geiger, C; Kriegl, L; Reinisch, A; Keldorfer, M; Wölfler, A; Wallner, M; von, Lewinski, D; Eller, P; Krause, R.
Triazoles Versus Echinocandins for the First-Line Treatment of Invasive Pulmonary Aspergillosis: A Propensity Score-Weighted Multicenter Study.
Open Forum Infect Dis. 2025; 12(12): ofaf709
Doi: 10.1093/ofid/ofaf709
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Hatzl Stefan
- Krause Robert
- Co-Autor*innen der Med Uni Graz
- Eller Philipp
- Geiger Christina
- Keldorfer Markus
- Kriegl Lisa
- Reinisch Andreas
- von Lewinski Dirk
- Wallner Markus
- Wölfler Albert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Triazoles (eg, isavuconazole, posaconazole, voriconazole) are the first-line treatment for invasive pulmonary aspergillosis (IPA), but their use can be limited by drug interactions, hepatotoxicity, and emerging azole resistance. Recent guidelines recommend echinocandins as a safe and well-tolerated first-line alternative. METHODS: In this multicenter observational study across 9 treatment centers, we included all consecutive patients with IPA from 1 January 2014 to 1 June 2024. We compared 30-day overall survival (OS) as the primary outcome and 90-day OS as the secondary outcome between patients receiving triazoles versus echinocandins as first-line therapy. Propensity score adjustment was applied to address baseline characteristic imbalances. RESULTS: We included 177 patients, of whom 153 (86%) received triazoles as first-line therapy (69 voriconazole, 54 isavuconazole, 30 posaconazole). Before propensity score adjustment, patients treated with echinocandins were significantly sicker, with higher rates of intensive care treatment (95% vs 75%, P = .002). In both crude and propensity score-adjusted analyses, 30-day mortality was significantly higher in the echinocandin group compared to the triazole group (63% [95% CI 55-70] vs 30% [95% CI 13-50], P < .001). Even switching from echinocandins after initial treatment failure to salvage therapy did not mitigate the negative impact on OS. Switching from triazoles (28/153 cases) was mainly due to tolerability concerns, while echinocandins (12 cases) were switched for treatment failure. CONCLUSIONS: Using echinocandins as alternative first-line treatment for IPA may result in poorer survival outcomes and should be approached with caution until further trials confirm our findings.
- Find related publications in this database (Keywords)
- aspergillosis
- critically ill
- echinocandins
- ICU
- immunocompromised
- triazoles